GM1 Oligosaccharide Ameliorates Rett Syndrome Phenotypes In Vitro and In Vivo via Trk Receptor Activation

Area of Science:

• Neuroscience
• Genetics
• Biochemistry

Background:

• Rett syndrome (RTT) is a severe neurodevelopmental disorder linked to mutations in the methyl-CpG binding protein 2 (MECP2) gene.
• Current treatments are limited due to incomplete understanding of MECP2 deficiency's molecular impact.
• Key pathological factors include impaired neurotrophin signaling and mitochondrial dysfunction.

Purpose of the Study:

• To investigate the therapeutic potential of GM1-OS, the oligosaccharide chain of GM1 ganglioside, in ameliorating RTT deficits.
• To explore the underlying mechanisms of GM1-OS action in RTT models.

Main Methods:

• Utilized Mecp2-knock-out (ko) mouse models and primary cortical neurons.
• Administered GM1-OS both in vitro and in vivo.
• Assessed synaptogenesis, mitochondrial oxidative stress, and RTT-like symptoms.

Main Results:

• GM1-OS treatment restored synaptogenesis in Mecp2-ko cortical neurons.
• GM1-OS reduced mitochondrial oxidative stress in Mecp2-ko neurons.
• In vivo administration of GM1-OS mitigated RTT-like symptoms in the mouse model.

Conclusions:

• GM1-OS effectively ameliorates RTT deficits by restoring neuronal homeostasis.
• The therapeutic effects of GM1-OS are mediated through activation of Trk receptors.
• GM1-OS represents a promising therapeutic candidate for Rett syndrome treatment.